Last updated on February 2019

PF-06804103 Dose Escalation in HER2 Positive Solid Tumors

Brief description of study

The study will evaluate the safety, pharmacokinetics and pharmacodynamics of increasing doses of PF-06804103 in patients with HER2 positive solid tumors. The study will expand to look at the selected dose in patients with breast cancer, gastric cancer and non-small cell lung cancer

Clinical Study Identifier: NCT03284723

Contact Investigators or Research Sites near you

Start Over

UCLA Hematology/Oncology

Los Angeles, CA United States
  Connect »

Samsung Medical Center

Seoul, Korea, Republic of
  Connect »

Cedars-Sinai Medical Center

Los Angeles, CA United States
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.